Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 1999

View Archived Issues

VEGF-B gene patents and technology licensed to RPR Gencell

FDA grants marketing clearance for Panretin Gel

ABS patent application for epilepsy drug allowed in Japan

Novel mast cell inhibitor tested preclinically for allergy prevention

Modulators of nAChR a focus of research at NeuroSearch

New Celgene compounds reduceTNF-alpha levels and NF-kB activity

Cytokine inhibitors in development at Sumitomo for AIDS and other disorders

Plant-derived antiviral agents for AIDS disclosed by Tsumura

Subgroup-selective integrin binding inhibitors patented by Celltech

Novel semisynthetic macrolide antibiotics developed at Abbott

Overview of phase II trials of GV-150526 presented

Preliminary clinical results presented for YM-872, a potential therapeutic for stroke

CNS-5161 safe for further clinical evaluation as a neuroprotective agent

Abgenix reports positive preliminary results from phase II trial of GVHD treatment

Approval sought for intravenous Hectorol; FDA review status updated

Successful phase II trial of chronic bronchitis treatment reported by Milkhaus

AT1-targeted antisense approach to hypertension validated in vitro and in vivo

Vitaxin proceeds to phase II

Novel ferrioxamine immunosuppressant discovered at Japanese research institutes

Viragen completes toxicology studies of Omniferon

LeuTech phase II study for osteomyelitis commences

AIDS conference serves as forum for highlighting new Vertex/Glaxo Wellcome HIV protease inhibitor

Aronex's NDA for Atragen accepted for review